Trials / Conditions / BRCA2 Mutation Carrier

BRCA2 Mutation Carrier

20 registered clinical trials studyying BRCA2 Mutation Carrier.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Ca NCT01905046	Alliance for Clinical Trials in Oncology	Phase 3
Completed	Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy NCT02314156	Northwestern University	Phase 2
Active Not Recruiting	mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian NCT02208375	M.D. Anderson Cancer Center	Phase 1
Completed	Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cance NCT01874184	University of Washington	N/A
Completed	Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Per NCT01540565	National Cancer Institute (NCI)	Phase 2
Completed	S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer NCT01097278	SWOG Cancer Research Network	N/A
Terminated	Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors NCT01233505	National Cancer Institute (NCI)	Phase 1
Completed	Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer NCT01219075	University of Southern California	N/A
Completed	ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors NCT01154426	National Cancer Institute (NCI)	Phase 1
Completed	Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer NCT00986206	Women and Infants Hospital of Rhode Island	—
Completed	Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy NCT00892736	National Cancer Institute (NCI)	Phase 1
Withdrawn	Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers NCT00899145	Gynecologic Oncology Group	—
Completed	Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation NCT00673335	UNICANCER	Phase 3
Unknown	Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers NCT00897455	Gynecologic Oncology Group	—
Completed	Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metast NCT00664781	Cancer Research UK	Phase 2
Completed	Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer NCT00535119	National Cancer Institute (NCI)	Phase 1
Completed	Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer NCT00321633	University College London Hospitals	Phase 2
Completed	Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer an NCT00098800	University of Arizona	N/A
Active Not Recruiting	Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopa NCT00080756	City of Hope Medical Center	Phase 2
Withdrawn	Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Proph NCT00084370	University of Alabama at Birmingham	N/A